摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
摘要:
A compound of the formula (I) in which R1 is —OR11, —SR11, —SOR11, —SO2R11, —NHR11, or —NR12R13 , and R11, R12, and R13 are as defined broadly in the text. R2 is H, C1-C6alkyl, carbamoyl, or an ester group. R3 is thienyl, pyridyl optionally substituted by halogen or C1-C6alkoxy; naphthyl optionally substituted by C1-C6alkoxy; dioxane fused phenyl; dioxacyclopentane fused phenyl; or optionally substituted phenyl. Y is CH or N. A process for preparing such compounds, pharmaceutical compositions containing such compounds, and a method of treating asthma using them are also disclosed and claimed.
摘要翻译:其中R 1为-OR 11,-SR 11,-SOR 11的式(I)化合物, SO 2,-SO 2,R 11,-NHR 11或-NR 12 R 13 < / SUP>和R 11,R 12和R 13如在文中广义地定义的。 R 2是H,C 1 -C 6烷基,氨基甲酰基或酯基。 R 3是噻吩基,任选被卤素或C 1 -C 6烷氧基取代的吡啶基; 任选被C 1 -C 6烷氧基取代的萘基; 二恶烷稠合苯基; 二氧杂环戊烷稠合苯基; 或任选取代的苯基。 Y是CH或N.一种制备这种化合物的方法,含有这些化合物的药物组合物和使用它们治疗哮喘的方法也被公开和要求保护。
摘要:
An ATM switching system concentrates cell streams, which are output by respective ones of a plurality of line interfaces, by a concentrator, enters a resulting cell stream into an ATM switch unit, deconcentrates cells, which have been switched by the ATM switch unit, by a deconcentrator on a per line interface basis and sends the cells to lines. Each line interface converts a VPI/VCI included in the header of a cell that has entered from a line to an internal cell address having a number of bits smaller than the number of bits of the VPI/VCI. Each unit in the ATM switching system performs management of various data and controls cell switching based upon a converted cell address without relying upon the VPI/VCI. The line interface restores an internal cell address, which is included in the header of a cell that enters from the side of the ATM switch, to the VPI/VCI and sends the cell to a line.